An observational study in Trigeminal Neuralgia, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of Minnesota · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is one of 5 that started in 2022, is one of 8 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 28th registered.
140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.
Browse Trigeminal Neuralgia studies →7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The Foundation for Orthopaedics and Regenerative Medicine · Sites in United States, Greece
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Healthy volunteers
The Radiosurgery Society · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 1997; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 84 across 38 observational studies indexed under Trigeminal Neuralgia.
Median enrollment 29 across the 26 interventional studies, 56 across the 8 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 34 have an industry lead sponsor. The 10 most frequent:
University of Minnesota is the lead sponsor of 1,219 studies on the registry; 199 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
University of Minnesota has 3 studies filed under Trigeminal Neuralgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Trigeminal Neuralgia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05217628Phase 3Noema Pharma AGAn Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | 2027-02-02 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT06216886Stanford UniversityOnabotulinumtoxinA for Trigeminal Neuralgia | 2027-02-01 |
| NCT05269472University of MinnesotaTrigeminal Neuralgia Electrophysiology | 2027-11-01 |
| NCT05738096University of MinnesotaTrigeminal Evoked Responses to Improve Rhizotomy | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study intervention is to perform standard somatosensory evoked responses limited to the face during rhizotomy procedures of the gasserian ganglion (trigeminal ganglion) for the treatment of trigeminal neuralgia. The evoked responses will be measured at two locations before and after the clinical rhizotomy including: the standard contralateral scalp (EEG) and at the gasserian ganglion through an FDA-approved recording electrode.
Adults of 18 years or older who are scheduled to undergo percutaneous rhizotomy for facial pain
Inclusion Criteria (TGN):
Exclusion Criteria (TGN):
Inclusion Criteria (Healthy controls)
Exclusion Criteria (Healthy Controls)
Procedure: Trigeminal Electrophysiology
This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
Determine the feasibility of measuring trigeminal somatosensory evoked potentials to improve personalized mapping during percutaneous rhizotomy
percentage of consented participants who complete the study
Time frame: 3 years
Started Apr 2022 (actual). Primary completion is estimated for Nov 2027, 66 months after the start.
Of 19 observational studies under Trigeminal Neuralgia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 66 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Apr 2027 → Nov 2027 and completion Apr 2027 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.